Abstract. Cerebral vasospasm is one of the major complications of subarachnoid hemorrhage (SAH). The prevention and treatment of cerebral vasospasm thus plays a critical role in the management of SAH patients. However, the mechanism of cerebral vasospasm still remains elusive, while effective therapeutic strategies also remain to be established. The role of thrombin and its receptor proteinase-activated receptor 1 (PAR 1 ) in cerebral vasospasm was investigated using a rabbit double hemorrhage SAH model. The expression of PAR 1 was up-regulated and the contractile response to thrombin was markedly enhanced in the basilar artery of SAH models. The intrathecal administration of a PAR 1 antagonist prevented the up-regulation of PAR 1 and the enhancement of the contractile responses to thrombin in SAH. These observations thus suggest that PAR 1 may play a pivotal role in post-hemorrhagic cerebral vasospasm in SAH. Following SAH, thrombin activates PAR 1 , thereby up-regulating the expression of PAR 1 , which culminates in the increased contractile response to thrombin in the basilar artery. PAR 1 antagonists are thus anticipated to be a novel therapeutic strategy for cerebral vasospasm. However, further studies are needed before establishing the clinical usefulness of PAR 1 antagonists.
Introduction
Cerebral vasospasm is a phenomenon of the reversible narrowing of the cerebral arteries seen after a subarachnoid hemorrhage (SAH). In most cases, vasospasm begins as early as approximately 4 days after SAH, it thereafter reaches a maximal narrowing at 7 -10 days, and then resolves by 14 days. During this period, vasospasm may cause severe neurological deficits or even a fatal outcome. Therefore, cerebral vasospasm is a major determinant of the prognosis of SAH. Vasospasm can be detected by angiography in 40% -70% of SAH patients, while the symptomatic vasospasm is observed in about 20% -30% of the patients (1, 2) . Delayed ischemic neurological deficits due to cerebral vasospasm account for about 30% of the mortality and 34% of the morbidity, despite the otherwise successful treatment of cerebral aneurysms (2) . The prevention and treatment of cerebral vasospasm thus play an important role in the management of SAH. However, the mechanism of cerebral vasospasm still remains elusive, while efficient therapeutic strategies also remain to be established. In this mini-review, the current understanding of the mechanism of cerebral vasospasm and the current therapeutic strategies will first be briefly overviewed. Thereafter, the role of thrombin and proteinase-activated receptor 1 (PAR 1 ) in the increased contractile responsiveness of cerebral artery and the potential of PAR 1 antagonists as a novel therapeutic strategy for cerebral vasospasm will be herein discussed.
Current understanding of the mechanism of cerebral vasospasm
Cerebral vasospasm is conceivably caused by the increased production of spasmogens and/ or the increased responsiveness of the cerebral arteries (Table 1) . Various substances listed in Table 1 have been proposed as spasmogens. Among them, blood-derived and plateletderived substances are of particular interest because of their association with hemorrhage. On the other hand, the delayed onset of cerebral vasospasm may suggest the importance of the increased vascular responsiveness as a fundamental mechanism of cerebral vasospasm. Increased vascular responsiveness can be attributed to either endothelial dysfunction (3 -5) or increased contractility of the vascular smooth muscle (1) ( Table 1) . In this context, the spasmogens may contribute to vasospasm not only by directly constricting the arteries, but also by increasing the vascular responsiveness. For example, endothelial damage and dysfunction due to oxidative stress have been demonstrated in the cerebral artery after SAH (6) . An increase in the activity of Rho kinase has also been suggested to contribute to the increased contractility observed in SAH (7, 8) .
The involvement of thrombin in cerebral vasospasm has been suggested by several lines of evidence. A clinical study demonstrated that the incidence of posthemorrhagic vasospasm correlated with the amount of peri-arterial blood clotting (9) . The thrombin activity in the cerebrospinal fluid correlated with the incidence and severity of cerebral vasospasm in SAH patients (10, 11) . The inhibition of the thrombin activity by antithrombin III or thrombin inhibitors (12) or the removal of clots in the subarachnoid space (13 -15) have been reported to be effective for the prevention of vasospasm.
However, the molecular mechanism by which thrombin contributes to cerebral vasospasm still remains unclear.
Current strategies for the treatment of cerebral vasospasm
Current strategies for the treatment of cerebral vasospasm are aimed at either preventing the development of vasospasm or reversing the constricted arteries ( Table 2 ). Clot removal, by either surgery (13) or intrathecal application of fibrinolytic agents such as urokinase or tissue plasminogen activator (16 -18) , has (10, 12, 35) , plasmin (36) , fibrin degradation products (55, 56) Platelet-derived substances: serotonin (57, 58) , thromboxane A2 (25, 59), platelet-derived growth factor (60) Prostaglandins: PGF2α (61, 62), PGE2 (63) Reactive oxygen species and related materials: lipid hydroperoxide (6) Lipid mediators: sphingosine 1-phosphate (64), arachidonic acid (65) Vasoactive substances: endothelin-1 (66, 67) , angiotensin II (57, 58) Increased vascular responsiveness Endothelial damage and dysfunction (3) Increased contractile responsiveness of smooth muscle Increased receptor function: PAR1 (42, 43) , PDGFR (68) Alteration of signaling proteins: increased activity of Rho kinase (7, 8) Table 2 . Current therapeutic strategies for the treatment of cerebral vasospasm
Prevention of cerebral vasospasm

Removal of the clots
Removal by surgery (13 -15) Removal with fibrinolytic agents
Urokinase (16) Tissue-plasminogen activator (17, 18) Triple-H (hypertensive, hypervolemic, hemodilution) therapy (19) Pharmacological agents Calcium-channel blockers (21, 22) Rho kinase inhibitor (23, 24) Thromboxane A2 synthetase inhibitor (25, 26) Statins (27, 28) Endothelin A-receptor antagonist (29, 30) Reversal of a constricted artery Balloon angioplasty (31) Pharmacological agents Papaverine (32, 33) Rho kinase inhibitor (34) been shown to reduce the incidence of cerebral vasospasm. These therapeutic effects are consistent with the observation that the incidence and severity of cerebral vasospasm correlated to the volume of the clot in the subarachnoid space (9) . Preserving the cerebral blood flow is suggested to be beneficial for reducing the rate or severity of delayed ischemic neurological deficits (19) . The triple-H regimen (hypertensive, hypervolemic, and hemodilution therapy) has been reported to be effective for this purpose (19) . However, one randomized controlled study reported that this therapy failed to increase the cerebral blood flow and reduce the incidence of the delayed ischemic neurological deficits (20) .
Various pharmacological agents have been used to prevent the development of cerebral vasospasm. Calciumchannel blockers, nimodipine and nicardipine, have been shown to improve the prognosis of SAH patients (21, 22) . One controlled study showed nimodipine reduces the incidence of severe neurologic deficits from 13.3% to 1.79% (21) . A Rho kinase inhibitor (23, 24) and thromboxane A 2 synthetase inhibitor (25, 26) also reduced the rate of cerebral vasospasm. The Rho kinase inhibitor reduced angiographic vasospasm from 61% to 38% and symptomatic vasospasm from 50% to 35% (24) . A thromboxane A 2 synthetase inhibitor significantly improved the occurrence of non-symptomatic to slightly symptomatic cerebral vasospasm from 59% to 37% (26) . The preventive effect of statins (27, 28) and an endothelin A-receptor antagonist (29, 30) have also been reported.
Once cerebral vasospasm develops, attempts to relieve the constricted arteries are made either by balloon angioplasty (31) or intra-arterial injection of vasodilator agents such as papaverine (32, 33) or Rho kinase inhibitor (34) . These treatments successfully dilate the constricted arteries and improved the neurological symptoms (31 -34) . However, balloon angioplasty may induce additional mechanical damage to the arteries. Vasodilator treatment may only produce limited vasodilatation with a single injection. Repeated injections may thus be required to obtain optimal vasodilatation.
Role of thrombin and PAR 1 in cerebral vasospasm
In 1975, White et al. demonstrated that thrombin induced contraction in the canine basilar artery (35) . Later, a link between thrombin and cerebral vasospasm in SAH was suggested by both clinical studies with SAH patients and experimental studies with animal models of SAH, as mentioned above (10 -12, 36) . However, the mechanism by which thrombin induces cerebral vasospasm remains unclear. The first thrombin receptor, PAR 1 , was identified in 1991. Later, three more subtypes have been identified, including receptors for other proteinases. Among the 4 subtypes, PAR 1 , PAR 3 , and PAR 4 serve as receptors for thrombin. In the vascular system, endothelial cells are known to express all 3 thrombin receptors and PAR 2 (37 -39). The vascular smooth muscle cells are known to express PAR 1 and PAR 2 (37). However, there has been no direct evidence for the expression of PAR 3 and PAR 4 in the vascular smooth muscle. PAR 1 is the major receptor mediating the vascular effects of thrombin, such as smooth muscle contraction and proliferation (37, 40, 41) . PAR 1 is thus suggested to play an important role in cerebral vasospasm. However, it still remains to be investigated. Therefore, the role of thrombin and PAR 1 in cerebral vasospasm was investigated using a rabbit double hemorrhage model of SAH (42, 43) .
The rabbit SAH model was prepared by injecting autologous blood into the cisterna magna on day 0 and day 2 (42, 43) . The control rabbits received injections of physiological saline solution in place of autologous blood, while intact rabbits received no intervention. The contractile responses and the expression of PAR 1 were investigated in the isolated basilar arteries. The contractile response to thrombin was markedly enhanced in SAH in comparison to those seen in the intact or the control rabbits (Fig. 1a) . The enhanced contractile response was also observed with PAR 1 -activating peptide (42, 43), but not activating peptides for PAR 2 or PAR 4 (43) . An immunoblot analysis revealed the up-regulation of the PAR 1 expression in the smooth muscle of basilar artery of SAH (Fig. 1b) . However, the contractile responses to high K + depolarization and endothelin-1 remained unaffected in SAH (42, 43) . The endothelium-dependent relaxations induced by acetylcholine and thrombin in SAH were similar to those seen in the control (42, 43) . Furthermore, the Ca 2+ -induced contractile responses and the GTPγS-induced contraction in the α-toxin-permeabilized preparations also remained unchanged in SAH (42) . These observations thus suggested that the enhanced contractile effect of thrombin was attributed mainly to the increased function of PAR 1 , but not a general enhancement of the contractile mechanism. The up-regulation of PAR 1 is considered to play a major role in the increased function of PAR 1 . Heparinization of autologous blood before injection significantly attenuated the enhancement of the contractile responses to thrombin (42) , thus suggesting that thrombin is responsible for the increased receptor function and the enhanced contractile responses seen in SAH. Therefore, the preventive effect of PAR 1 antagonists was investigated. PAR 1 antagonists are distinguished from thrombin inhibitors or heparin in that they have no inhibitory effect on the proteolytic activity of thrombin but they antagonize the activation of the receptor following the thrombin cleavage of PAR 1 . Therefore, PAR 1 antagonists are capable of inhibiting the cellular effects of not only thrombin but also PAR 1 -activatging peptides. The intrathecal injections of PAR 1 antagonist together with autologous blood dosedependently inhibited the enhancement of the contractile response to thrombin (Fig. 1c) and the up-regulation of the PAR 1 expression in SAH (Fig. 1d) . Accordingly, the schematic drawing shown in Fig. 2 shows the proposed role of thrombin and PAR 1 in the increased vascular responsiveness of basilar artery in SAH. Thrombin, which is activated following SAH, cleaves and activates PAR 1 , thereby up-regulating the expression of PAR 1 in smooth muscle of the basilar artery, which culminates in the increased responsiveness of the basilar artery toward thrombin on days 5 -7. In this scheme, the PAR 1 antagonist is considered to antagonize the effect of thrombin on the expression of PAR 1 , thus preventing the receptor up-regulation and the enhancement of the contractile response to thrombin. In addition, a PAR 1 antagonist directly antagonized the contractile effect of thrombin (43) , which may help to relieve the constricted cerebral artery. In conclusion, PAR 1 is suggested to play a pivotal role in cerebral vasospasm not only by directly mediating the vasoconstricting effect of thrombin, but also and more importantly, by up-regulating the expression of itself and thereby increasing the responsiveness of the cerebral arteries. Thrombin is thus suggested to play an important role in cerebral vasospasm not just as a spasmogen but also as a factor that increases the vascular responsiveness.
Concluding remarks
These observations have revealed, for the first time, Fig. 1 . Prevention of the up-regulation of PAR1 and the enhancement of the contractile response to thrombin by intrathecal treatment with a PAR1 antagonist in the rabbit subarachnoid double hemorrhage model. a: The concentration-response curves for the thrombin-induced contraction in intact, control, and subarachnoid hemorrhage (SAH) rabbits. Control rabbits received two injections of physiological saline into the cisterna magna, while SAH model rabbits received injections of autologous blood. Intact rabbits received no intervention. b: Immunoblot analysis of the PAR1 expression in the basilar artery of SAH on the indicated days after the first injection of the autologous blood. Actin was detected by naphtol blue black staining to normalize the level of PAR1 expression. The level of PAR1 in intact arteries was designated to be 100%. c: The dose-dependent effect of the PAR1 antagonist E5555 on the increased contractile response to 1 unit/mL thrombin in SAH. E5555 was kindly donated by Eisai Co., Ltd. (Tokyo) (43) ; it was injected into the cisterna magna twice together with autologous blood. d: An immunoblot analysis of the PAR1 expression in the basilar artery of SAH with (+E5555) and without (SAH) treatment with E5555 (2 µg/kg weight/injection). Actin was detected by naphtol blue black staining. The level of PAR1 seen without E5555 was assigned to be 100%. All data represent the mean ± S.E.M. Fig. 2 . Proposed role of thrombin and PAR1 in cerebral vasospasm in subarachnoid hemorrhage. Thrombin, which is activated following the hemorrhage in the subarachnoid space, cleaves and activates PAR1, thereby up-regulating the expression of PAR1 and also increasing the contractile response of the basilar artery to thrombin. The PAR1 antagonist not only prevents the up-regulation of PAR1 and the enhancement of the contractile response, but also directly inhibits the contractile effect of thrombin.
that thrombin and PAR 1 play an important role in the increased vascular responsiveness in SAH. In this context, the receptor up-regulation is a key step for PAR 1 to contribute to the enhanced contractile response. The receptor up-regulation also plays a key role in other vascular diseases (41) . Although PAR 1 is known to contract arteries, this contractile effect of PAR 1 in normal arteries has been reported only in limited types of arteries (44 -46) . On the contrary, most of the normal arteries do not contract in response to thrombin, probably because the expression level of PAR 1 is low (47) . In vascular lesions such as those seen in atherosclerosis or balloon injury, the expression of PAR 1 is up-regulated in smooth muscle and the smooth muscle effects of PAR 1 thus become dominant, thereby contributing to development of vascular lesions and increased contractility (41) . SAH now can be added to the list of vascular diseases where the PAR 1 upregulation in smooth muscle plays a critical role. Therefore, elucidating the mechanism for the receptor up-regulation is thus essential for developing new therapeutic strategies for the prevention and treatment of vascular diseases. The mechanisms may differ with the type of vascular diseases (48) . In SAH, thrombin activation of PAR 1 is suggested to be responsible for the receptor up-regulation. Therefore, PAR 1 antagonists are anticipated to be a potentially effective therapeutic strategy for either preventing or treating cerebral vasospasm in SAH. However, the clinical usefulness of PAR 1 antagonists still remains to be established by further investigations, especially in humans.
